Pepper Hamilton Represents Amicus Therapeutics in Underwritten Offering of Common Stock
Amicus Therapeutics — a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases — announced on Feb. 21 the closing of its offering of common stock. Pepper Hamilton represented Amicus in the offering.
The company issued 19,354,839 shares in the offering, at a price of $15.50 per share. Amicus has granted the underwriters a 30-day option to purchase up to an additional 2,903,225 shares of its common stock. The gross proceeds from the offering to Amicus are expected to be $300 million.
The company expects to use the net proceeds of the offering for investment in the U.S. and international commercial infrastructure for migalastat HCl, investment in manufacturing capabilities for ATB200, the continued clinical development of its product candidates, research and development expenditures, clinical and pre-clinical trial expenditures, commercialization expenditures and for other general corporate purposes.
Pepper attorneys who advised on the offering included:
- Scott R. Jones, a partner in the Health Sciences Department, a team of 110 attorneys who collaborate across disciplines to solve complex legal challenges confronting clients throughout the health sciences spectrum
- Judith L. O’Grady, a partner in the Health Sciences Department
- Patrick J. Bianchi, an associate in the Corporate and Securities Department
- Alexander F. Joseph, an associate in the Corporate and Securities Department